Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

ID#: NCT06932081

Age: 18 years - 66+

Gender: All

Healthy Subjects: No

Recruitment Status: Recruiting

Start Date: January 01, 2023

End Date: December 31, 2027

Contact Information:
Ralph M.L. Neijenhuis, MD
+31 71 5262020
Anastasia D. Egorova, MD PhD
+31 71 5262020
Summary: This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Eligibility:

Inclusion Criteria:

- Congenital heart defect.

- Age ≥ 18 years.

- Initiated on treatment with an SGLT2i.

Exclusion Criteria:

- No consent for data collection.
Find a Clinical Trial Find Cancer Clinical Trials